The company is advancing a novel research platform built on highly purified cannabinoids that are free of THC and CBD, with an emphasis on inflammatory and autoimmune diseases. The company develops a lead product candidate for the treatment of rheumatoid arthritis and intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases.
Cyborg Score Rationale
The company shows significant operating challenges with negative operating income of $1.5M, negative operating cash flow of $532K, and a current ratio of 0.03 indicating short-term liquidity concerns. As a clinical-stage biotech, execution on its cannabinoid-based pipeline is critical to long-term viability.
Top Insights
Core focus on non-psychoactive cannabinoids (THC/CBD-free) for inflammatory and autoimmune diseases represents differentiation vs. broader cannabis industry
Lead program in rheumatoid arthritis with completed studies; asthma candidates in pre-clinical stage signal pipeline expansion
Traded on OTC markets as a micro-cap with material cash constraints limiting clinical development velocity
Technology platform emphasizes cannabinoid modulation of immune response and inflammatory pathways—addressing high unmet medical needs in RA, oncology, and autoimmune indications
Named Competitors
Rinvoq — JAK inhibitor for rheumatoid arthritis
Kevzara — IL-6 antagonist for RA
Opdivo — PD-1 inhibitor for oncology indications
GWP42006 — Cannabinoid-based therapeutic development
Recent Developments
(March 2026) Most recent SEC filing submitted showing financial statements and operational updates
(May 2021) Company completed share exchange, merging Israeli Raphael Pharmaceutical Ltd. with US-listed Easy Energy Inc.
Open the full interactive Raphael Pharmaceutical Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.